Drug Development Drug Mechanisms Psychoactive Substances Drug Safety Cannabinoids Opioids Psychedelics Hormones Synthetic Drugs GLP-1 Receptor Agonists Drug Research Natural Products Drug Effects Veterinary Medicine GLP-1 Agonists Drug Mechanism Psychedelic Research Drug Classification Psychedelic Substances Opioid Potency Opioid Receptors Ketamine Psychedelic Compounds Immunotherapy Antiviral Drugs Drug Comparisons Peptides Natural Alkaloids Endocrinology Glutathione Drugs Cancer Research Sildenafil Ocular Pharmacology GLP-1 Drugs Medication Effects Isoxazolines Herbal Pharmacology Pharmacokinetics Environmental Health Drug Studies Immunotherapy Research Opioid Effects Plant-Based Compounds Adrenoceptors Kratom Effects Drug Absorption Herbal Drug Identification Addictive Substances Drug Efficacy Medication for Menstrual Disorders Receptor Agonists Clinical Trials Pharmacopoeia Dental Products Medicinal Chemistry Toxicology Vitamin B9 Antidote Development Antidotes Experimental Drugs Doping Research Tyrosine Kinase Inhibitors Psychoactive Compounds Synthetic Compounds Drug Design Therapeutics Psychedelic Therapy Drug Effectiveness Gut Hormones Emergency Contraceptives Medicinal Claims Medical Gases Hormonal Treatments Performance-Enhancing Drugs Drug Composition Xylazine Mifepristone Ruling Applied Physical Sciences Psychedelic Drugs Anesthetic Drugs Anabolic Steroids Medication Cannabis Research Neurotransmitters Drug Synergy
The UCLA-led JAMA review urges clinician caution, citing weak evidence for common uses alongside measurable harms.
